Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity award transaction rather than consolidated financial performance.
Material Changes
The material change reported is an increase in shareholding for a connected person of a PDMR:
- Transaction Type: Award under the GlaxoSmithKline 2009 Performance Share Plan.
- Date of Award: February 17, 2012.
- Shares Awarded: 1,942 Ordinary Shares.
- Reference Price: £14.14 per share (closing middle market price on the award date).
- Beneficiaries: Mr. P Thomson (PDMR) and Mrs. K Thomson (Connected Person).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary contingency noted is that the vesting of the awarded shares is subject to meeting performance criteria over a three-year period. No unusual items or specific risks were disclosed in this notification.
Investor Verification Checklist
- Verify the vesting conditions and performance criteria for the 2009 Performance Share Plan.
- Confirm the total shareholding of Mr. P Thomson and Mrs. K Thomson post-award.
- Review the company's broader 20-F annual report for comprehensive financial metrics not included in this 6-K.